Produção Nacional
Revisado por pares
NFATc1 and TNFα expression in giant cell lesions of the jaws
2010; Wiley; Volume: 39; Issue: 3 Linguagem: Inglês
10.1111/j.1600-0714.2009.00855.x
ISSN1600-0714
AutoresFabrício Rezende Amaral, João Artur Ricieri Brito, Paôlla Freitas Perdigão, Vinícius Magalhães Carvalho, Paulo Eduardo Alencar Souza, Marcus V. Gomez, Luiz Marco, Ricardo Santiago Gomez,
Tópico(s)Ubiquitin and proteasome pathways
ResumoJournal of Oral Pathology & MedicineVolume 39, Issue 3 p. 269-274 NFATc1 and TNFα expression in giant cell lesions of the jaws Fabrício Rezende Amaral, Fabrício Rezende Amaral Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorJoão Artur Ricieri Brito, João Artur Ricieri Brito Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorPaôlla Freitas Perdigão, Paôlla Freitas Perdigão Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorVinícius Magalhães Carvalho, Vinícius Magalhães Carvalho Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorPaulo Eduardo Alencar De Souza, Paulo Eduardo Alencar De Souza School of Dentistry, Pontifícia Universidade Católica de Minas GeraisSearch for more papers by this authorMarcus Vinícius Gomez, Marcus Vinícius Gomez Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorLuiz De Marco, Luiz De Marco Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorRicardo Santiago Gomez, Ricardo Santiago Gomez Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this author Fabrício Rezende Amaral, Fabrício Rezende Amaral Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorJoão Artur Ricieri Brito, João Artur Ricieri Brito Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorPaôlla Freitas Perdigão, Paôlla Freitas Perdigão Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorVinícius Magalhães Carvalho, Vinícius Magalhães Carvalho Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this authorPaulo Eduardo Alencar De Souza, Paulo Eduardo Alencar De Souza School of Dentistry, Pontifícia Universidade Católica de Minas GeraisSearch for more papers by this authorMarcus Vinícius Gomez, Marcus Vinícius Gomez Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorLuiz De Marco, Luiz De Marco Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, BrazilSearch for more papers by this authorRicardo Santiago Gomez, Ricardo Santiago Gomez Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas GeraisSearch for more papers by this author First published: 18 February 2010 https://doi.org/10.1111/j.1600-0714.2009.00855.xCitations: 11 Ricardo S. Gomez, Laboratório de Biologia Molecular, Faculdade de Odontologia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, CEP 31.270-901, Belo Horizonte, Minas Gerais, Brazil. Tel: +55 31 3409 2477, Fax: +55 31 3409 2430, E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract J Oral Pathol Med (2010) 39: 269–274 Background: Activation mutations of SH3BP2 gene have been demonstrated in cherubism and central giant cell lesion (CGCL). In the present study we first attempted to investigate the SH3BP2 gene in peripheral giant cell lesion (PGCL). The effect of SH3BP2 gene mutations on the transcription of the downstream genes nuclear factor of activated T cells (NFATc1) and the cytokine tumor necrosis factor-α (TNF-α) was also investigated together with the immunolocalization of NFATc1 protein in a set of cases of PGCL, CGCL and cherubism with and without SH3BP2 mutation. Method: Fresh samples of five PGCL, five CGCL and one cherubism cases were included in this study. One of the samples of CGCL presented a somatic heterozygous mutation c.1442A>T in exon 11. The cherubism case showed a heterozygotic substitution c.320C>T in both blood and lesion. These mutations were previously published. All coding and flanking regions of the SH3BP2 gene were sequenced in the cases of PGCL. The real-time polymerase chain reaction (RT-PCR) was performed to analyze the transcription of NFATc1 and TNF-α genes. The immunohistochemical analysis of the NFATc1 protein was also performed. Results: No SH3BP2 gene mutation was found in PGCL. The RT-PCR showed increased expression of NFATc1 and decreased transcription of TNF-α in all the samples. The immunohistochemical analysis of the NFATc1 protein showed a predominant nuclear staining in the multinucleated giant cells. Conclusion: The development of giant cells lesions of the jaws and cherubism are possibly mediated by overexpression of NFAT in the nucleus of the multinucleated cells. References 1 Katsikeris N, Kakarantza-Angelopoulou E, Angelopoulos AP. Peripheral giant cell granuloma. Clinicopathologic study of 224 new cases and review of 956 reported cases. Int J Oral Maxillofac Surg 1998; 17: 94–9. 2 Carinci F, Piattelli A, Martinelli M, et al. Genetic profiling of central giant cell granuloma of the jaws. J Craniofac Surg 2005; 16: 399–407. 3 De Lange J, Van Den Akker HP, Van Den Berg H. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 603–15. 4 Horner K. Central giant cell granuloma of the jaws: a clinico-radiological study. Clin Radiol 1989; 40: 622–6. 5 Itonaga I, Hussein I, Kudo O, et al. Cellular mechanisms of osteoclast formation and lacunar in giant cell granuloma of the jaw. J Oral Pathol Med 2003; 32: 224–31. 6 Liu B, Yu SF, Li TJ. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med 2003; 32: 367–75. 7 Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 765–72. 8 Hyckel P, Berndt A, Schleier P, et al. Cherubism – new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg 2005; 33: 61–8. 9 Kaugars GE, Niamtu J 3rd, Svirsky JA. Cherubism: diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors. Oral Surg Oral Med Oral Pathol 1992; 73: 369–74. 10 Bell SM, Shaw M, Jou YS, Myers RM, Knowles MA. Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics 1997; 44: 163–70. 11 Ren R, Mayer BJ, Cichetti P, Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science 1993; 259: 1157–61. 12 Ueki Y, Tiziani V, Santanna C, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125–6. 13 De Lange J, Van Maarle MC, Van Den Akker HP, Redeker EJ. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 378–81. 14 Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM. Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. Br J Oral Maxillofac Surg 2008; 46: 229–30. 15 De Lange J, Van Maarle MC, Van Den Akker HP, Redeker EJW. DNA analysis of the SH3BP2 gene in patients with aggressive central giant cell granuloma. Br J Oral Maxillofac Surg 2007; 45: 499–500. 16 Lietman SA, Prescott NL, Hicks DG, Westra WH, Levine MA. SH3BP2 is rarely mutated in exon 9 in giant cell lesion outside cherubism. Clin Orthop Relat Res 2007; 459: 22–7. 17 Carvalho VM, Perdigão PF, Amaral FR, Souza PE, De Marco L, Gomez RS. Novel mutations in the SH3BP2 gene associated with sporadic central giant cell and cherubism. Oral Dis 2009; 15: 106–10. 18 Lietman SA, Kalinchinko N, Deng X, Kohanski R, Levine MA. Identification of a novel mutation of SH3BP2 in ceherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat 2006; 27: 717–8. 19 Lietman SA, Yin L, Levine MA. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Byophys Res Commun 2008; 371: 644–8. 20 Novack D, Faccio R. Jawing about TNF: new hope for cherubism. Cell 2007; 128: 15–7. 21 Ueki Y, Lin CI, Senoo M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 'cherubism' mice. Cell 2007; 128: 71–83. 22 Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, Van Der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503. 23 Imai Y, Kanno K, Moriya T, et al. A missense mutation in the SH3BP2 gene on chromosome 4p 16.3 found in a case of non-familial cherubism. Cleft Palate Craniofac J 2003; 40: 632–38. 24 Hounoki H, Sugiyama E, Mohamed SG, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone 2008; 42: 765–74. 25 Takayanagi H. Mechanism insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005; 83: 170–9. 26 Asagiri M, Takayanagi H. The molecular understanding osteoclast differentiation. Bone 2007; 40: 251–64. 27 Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005; 115: 3418–27. 28 Foucalt I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 2005; 105: 1106–13. 29 Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007; 1116: 227–37. 30 Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 2008; 22: 176–85. Citing Literature Volume39, Issue3March 2010Pages 269-274 ReferencesRelatedInformation
Referência(s)